Amycretin vs Semaglutide: Is Novo's Dual GLP-1/Amylin Agonist the Next-Generation Incretin?
Amycretin's Phase 1b/2 trial showed ~22% weight loss vs ~10.6% for semaglutide 2.4 mg at 26 weeks. Compare mechanisms, evidence, and 2026 regulatory status.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
Amycretin vs semaglutide is one of the most closely watched head-to-head comparisons in obesity research, since amycretin is the first unimolecular compound designed to combine GLP-1 and amylin receptor agonism against the field's dominant GLP-1 monotherapy benchmark. Researchers studying next-generation incretin pharmacology have used the published Phase 1b/2 head-to-head trial to ask whether dual-receptor engagement in a single molecule can outperform selective GLP-1 receptor agonism on weight-loss magnitude, tolerability, and dosing convenience.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: In a Phase 1b/2 randomized, double-blind, double-dummy trial published in The Lancet, subcutaneous amycretin produced approximately 22% mean body weight reduction at 26 weeks compared to approximately 10.6% with semaglutide 2.4 mg, but amycretin remains investigational while semaglutide is FDA-approved and has a decade of post-market safety data.
TL;DR:
- Amycretin is a unimolecular GLP-1/amylin receptor dual agonist (Novo Nordisk); semaglutide is a selective GLP-1 receptor agonist.
- Head-to-head Phase 1b/2 data (Lancet, 2024) showed ~22% weight loss for amycretin vs ~10.6% for semaglutide 2.4 mg at 26 weeks.
- Semaglutide is FDA-approved (Ozempic/Wegovy); amycretin is investigational, with Phase 3 REDEFINE obesity trials enrolling as of Q1 2026.
- Both engage overlapping but distinct satiety circuits — GLP-1 receptor signaling plus, for amycretin, amylin/calcitonin receptor complex activation in the area postrema.
- An oral amycretin formulation is in early-phase development, mirroring the oral-peptide trend already established with semaglutide.
Semaglutide: mechanism and evidence base
Semaglutide is a selective glucagon-like peptide-1 (GLP-1) receptor agonist that has served as the reference standard for injectable incretin therapy in obesity and type 2 diabetes research since its approval. Structurally, semaglutide carries an Aib-8 substitution that confers resistance to DPP-4 enzymatic degradation, combined with a C18 fatty diacid side chain that promotes albumin binding and extends its circulating half-life to roughly 168 hours, supporting once-weekly subcutaneous dosing. Mechanistically, semaglutide activates GLP-1 receptors concentrated in the hypothalamus and brainstem, enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central satiety circuits.
The evidence base behind semaglutide includes the SUSTAIN, STEP, and SELECT trial programs, which established its efficacy on HbA1c reduction, body weight, and cardiovascular outcomes. Full receptor pharmacology and signaling detail is covered in the site's dedicated semaglutide mechanism of action research guide and mechanism deep-dive article. A more recent case report (PMID 42027588) also documented a rare instance of reversible central respiratory depression following semaglutide dose escalation, illustrating that GLP-1 receptor expression outside classical metabolic tissue — in this case, brainstem respiratory control centers — remains an active area of pharmacovigilance research even for a compound this well studied.
Amycretin: mechanism and evidence base
Amycretin (NNC0385-0434, later-stage designation zenagamtide) is a first-in-class, unimolecular GLP-1 and amylin receptor dual agonist developed by Novo Nordisk. Unlike fixed-dose combination products such as CagriSema, which pair two separate molecules, amycretin is engineered as a single peptide capable of activating both receptor systems simultaneously. The GLP-1 receptor component suppresses appetite via hypothalamic and brainstem circuits familiar from semaglutide research, while the amylin receptor component acts on the area postrema — a circumventricular structure outside the blood-brain barrier — to reduce meal size, slow gastric emptying, and suppress glucagon through a largely non-overlapping neural pathway.
The key evidence comes from a Phase 1b/2 randomized, double-blind, double-dummy trial published in The Lancet in December 2024 (PMID 39626360), which directly compared subcutaneous amycretin to semaglutide 2.4 mg over 26 weeks in adults with overweight or obesity. In a separate Phase 2 dose-finding study in type 2 diabetes (NCT06542874), subcutaneous zenagamtide 40 mg achieved up to 14.6% weight loss and 89.1% of participants reaching HbA1c below 7% at 36 weeks, data presented at ADA 2026. An oral amycretin formulation has also produced early-phase results of approximately 13.1% weight loss at 12 weeks. Phase 3 obesity trials under the REDEFINE program began enrolling in Q1 2026, and a Phase 3 type 2 diabetes program is planned for the second half of 2026. Compound-level detail, including chemistry and full trial listings, is maintained on the amycretin library profile.
Side-by-side comparison
| Factor | Semaglutide | Amycretin (zenagamtide) |
|---|---|---|
| Receptor target | GLP-1 receptor (selective) | GLP-1 receptor + amylin receptor (dual, unimolecular) |
| Developer | Novo Nordisk | Novo Nordisk |
| Regulatory status | FDA-approved (Ozempic, Wegovy) | Investigational — no approval as of mid-2026 |
| Reported weight loss (head-to-head, 26 wk) | ~10.6% | ~22% |
| Route studied | Subcutaneous, oral (Rybelsus) | Subcutaneous and oral formulations in trials |
| Development stage | Marketed | Phase 3 (obesity); Phase 2 completed (T2D) |
| 503A compounding eligibility | Included on some compounding lists historically | Not 503A eligible (investigational) |
| Primary citation | PMID 42027588 | PMID 39626360 |
Differential research applications
Researchers select semaglutide when a well-characterized, single-receptor GLP-1 agonist with an extensive safety and outcomes record is the priority — for example, in comparative-effectiveness designs, cardiovascular outcome extensions building on SELECT, or as the active comparator arm in trials of newer multi-receptor candidates, which is exactly the role it plays in the amycretin Lancet trial itself. Amycretin, by contrast, is being studied specifically to test whether adding non-overlapping amylin receptor engagement to GLP-1 agonism produces additive rather than redundant satiety signaling, a question relevant to researchers investigating whether current weight-loss ceilings are receptor-limited or dose-limited. Because dosing, titration schedules, and reconstitution requirements differ substantially between an approved product and an investigational biologic still in Phase 3, researchers cross-referencing study protocols often use the site's peptide half-life and dosing reference tools alongside the clinical trial tracker to monitor REDEFINE program milestones as they are posted to registries.
Amycretin is not the only compound testing whether a second receptor mechanism can outperform GLP-1 monotherapy. Tirzepatide pairs GLP-1 agonism with GIP receptor activation rather than amylin, and cagrilintide pursues a similar amylin-GLP-1 strategy to amycretin but as a two-molecule fixed-dose combination rather than a single unimolecular peptide. Comparing amycretin's unimolecular design against cagrilintide's combination-product approach is a useful research lens for evaluating whether co-formulation complexity affects pharmacokinetics or real-world dosing convenience, since both are ultimately testing the same underlying hypothesis about additive amylin-GLP-1 signaling.
Regulatory and compounding status
Semaglutide holds full FDA approval under the brand names Ozempic (type 2 diabetes) and Wegovy (chronic weight management), and its compounded versions have been the subject of extended FDA enforcement discretion during supply shortages, a status that has shifted repeatedly as manufacturer supply has stabilized. Amycretin carries no regulatory approval in any jurisdiction as of mid-2026; it remains an investigational new drug studied exclusively within IND-authorized clinical trial protocols, and it is not eligible for 503A pharmacy compounding as an unapproved, non-bulk-drug-substance-listed compound. Researchers tracking how these statuses may change should treat the REDEFINE Phase 3 readouts, expected through 2026 and beyond, as the next major regulatory inflection point for amycretin specifically.
Cited studies
- PMID 39626360 — "Subcutaneous amycretin versus semaglutide 2.4 mg in adults with overweight or obesity: a randomised, double-blind, double-dummy, phase 1b/2 trial" (The Lancet, 2024/2025). DOI: https://doi.org/10.1016/S0140-6736(24)02496-8
- PMID 42027588 — "Unexplained hypercapnia with normal pulmonary evaluation in a patient receiving semaglutide: a diagnostic challenge" (2026). DOI: https://doi.org/10.1056/NEJMoa1607141
- NCT06542874 — Phase 2 dose-finding study of subcutaneous zenagamtide (amycretin) in type 2 diabetes, data presented at ADA 2026 (registry reference, ClinicalTrials.gov).
Frequently asked questions
Q: Is amycretin the same as semaglutide?
A: No. Amycretin is a distinct unimolecular compound engineered to activate both the GLP-1 receptor and the amylin receptor, while semaglutide is a selective GLP-1 receptor agonist only. They share the same developer, Novo Nordisk, and overlapping GLP-1 pharmacology, but amycretin's added amylin receptor activity is the defining mechanistic difference studied in head-to-head trials.
Q: How much more weight loss did amycretin show compared to semaglutide in trials?
A: In the Phase 1b/2 head-to-head trial published in The Lancet (PMID 39626360), subcutaneous amycretin produced approximately 22% mean body weight reduction at 26 weeks, compared to approximately 10.6% for semaglutide 2.4 mg over the same period. These figures come from a single trial and researchers generally await Phase 3 confirmation before treating early-phase magnitudes as durable.
Q: Is amycretin FDA-approved?
A: No. As of mid-2026, amycretin (zenagamtide) remains investigational, with Phase 3 obesity trials under the REDEFINE program enrolling since Q1 2026 and a Phase 3 type 2 diabetes program planned for the second half of 2026. It has not received FDA or other regulatory approval.
Q: Does amycretin have an oral formulation like semaglutide's Rybelsus?
A: Yes, an oral amycretin formulation is under early-phase development, with Phase 1 data showing approximately 13.1% weight loss at 12 weeks. This mirrors the oral-peptide delivery approach Novo Nordisk previously established with oral semaglutide (Rybelsus), though amycretin's oral program remains considerably earlier in development.
Q: Why is amylin receptor co-agonism considered significant in obesity research?
A: Amylin receptors are expressed at high density in the area postrema, a brainstem structure outside the blood-brain barrier that governs meal-size and satiety signaling through pathways largely distinct from GLP-1 receptor circuits. Researchers studying amycretin, and related amylin-GLP-1 combinations such as CagriSema, are testing whether engaging both pathways simultaneously produces additive weight-loss effects beyond what selective GLP-1 receptor agonism alone can achieve.
See also:
- Semaglutide Mechanism of Action: GLP-1 Receptor Agonism in Preclinical Research — deeper mechanistic detail on the GLP-1 receptor pathway both compounds share.
- Cagrilintide vs Semaglutide: Amylin-GLP-1 Combination vs GLP-1 Monotherapy in Metabolic Research — a related amylin-GLP-1 combination strategy using two separate molecules instead of one.
- Next-Generation GLP-1/Incretin Pipeline 2026: 9 Emerging Compounds Beyond Semaglutide and Tirzepatide — how amycretin fits into the broader investigational incretin landscape.
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.